nnvc
Il contropiano Del Vecchio-Caltagirone per Generali: osare di più, governance top e Bca Generali polo aggregante del risparmio gestito
Banca Generali sarebbe al centro del contropiano che Francesco Gaetano Caltagirone, Leonardo Del Vecchio e Fondazione Crt intendono presentare dopo il 15 dicembre, data prevista per la presentazione del business …
Torna l’ottimismo e gli investitori fanno il pieno dei pesi massimi di Piazza Affari, +3% Intesa Sanpaolo ed Enel
Gli investitori tornano ad acquistare massicciamente l’azionario con un convinto rimbalzo a inizio settimana. Piazza Affari si accoda all’ottimismo di Wall Street con le confortanti indicazioni circa il tasso di …
Per Musk scoppia la grana pannelli solari, SEC indaga e titolo Tesla esce dal $1 Trillion Club
Tesla è sotto indagine normativa della SEC dopo che un informatore ha affermato che la società di Elon Musk non ha informato adeguatamente i suoi azionisti e il pubblico circa …
Tutti gli articoli
Tutti gli articoli Tutte le notizie

  1. #1
    L'avatar di axelvento
    Data Registrazione
    Dec 2004
    Messaggi
    16,156
    Mentioned
    0 Post(s)
    Quoted
    33 Post(s)
    Potenza rep
    42949689

    nnvc

    passata da poco bb,,,,
    Immagini Allegate Immagini Allegate nnvc-mx.gif 

  2. #2

    Data Registrazione
    Apr 2006
    Messaggi
    2,623
    Mentioned
    0 Post(s)
    Quoted
    0 Post(s)
    Potenza rep
    0
    lo storico
    Immagini Allegate Immagini Allegate nnvc-0.png 

  3. #3

    Data Registrazione
    Apr 2006
    Messaggi
    2,623
    Mentioned
    0 Post(s)
    Quoted
    0 Post(s)
    Potenza rep
    0
    e lo zuuuumm
    Immagini Allegate Immagini Allegate nnvc-0.png 

  4. #4
    L'avatar di axelvento
    Data Registrazione
    Dec 2004
    Messaggi
    16,156
    Mentioned
    0 Post(s)
    Quoted
    33 Post(s)
    Potenza rep
    42949689
    wow $86 cents

    con volumi modesti,,,,,

  5. #5

  6. #6
    L'avatar di playars
    Data Registrazione
    Apr 2008
    Messaggi
    8,284
    Mentioned
    0 Post(s)
    Quoted
    1 Post(s)
    Potenza rep
    42949686
    The Company reported that it had approximately $7.68M in cash and approximately $486,000 in prepaid expenses and other cash equivalent assets as of September 30, 2010, the end of the reporting quarter. The shareholder equity stood at approximately $8.03M. In comparison, the Company had approximately $6.96M in cash, $501,000 in prepaid expenses and other cash equivalent assets, and $6.52M in shareholder equity as of the quarter ended June 30, 2010. The Company spent approximately $750,000 in Research and Development expenses (R&D) and approximately $361,000 in General and Administrative expenses (G&A) in the reported quarter. The Company’s rate of cash expenditure was in line with the Company’s budgeted targets.



    The Company has previously announced that Seaside 88, LP, a Florida limited partnership (“Seaside”), exercised their option to purchase an additional $2.5M of the Company’s Series B Convertible Preferred Stock. This amounted to net proceeds of approximately $2.295M to the Company after expensing commissions and legal fees. Seaside has also agreed to purchase an additional $2.5M of the Company’s Series B Convertible Preferred Stock within 90 days of the closing of the first follow on sale of the Company’s Series B Preferred Stock. The Series B Preferred Stock is convertible into a number of shares of the Company’s common stock every two weeks. The converted shares are estimated to represent less than five percent of the 10-day trading volume of the Company’s stock (OTC BB: NNVC.OB), based upon current data.



    The Company has no long term debt. The Company estimates that it currently has sufficient cash in hand to achieve the budgeted objectives for over 18 months of operations.



    The Company has reported satisfactory progress in its drug development objectives during this period. The Company reported that its anti-Herpes drug candidates demonstrated significant efficacy in cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy. Several of the anti-Herpes nanoviricides® demonstrated a dose-dependent maximal inhibition of Herpes virus infectivity in a cell culture model. Almost complete inhibition of the virus production was observed at clinically usable concentrations. These studies employed the H129 strain of herpes simplex virus type 1 (HSV-1). H129 is an encephalitic strain that closely resembles a clinical isolate; it is known to be more virulent than classic HSV-1 laboratory strains. The Company is now working on further optimizing these drug candidates, with a view towards animal studies. The H129 strain will be used in subsequent animal testing of nanoviricides for developing a skin cream to treat oral and genital herpes outbreaks.



    Subsequent to the quarterly report period, the Company recently announced that it has achieved profound levels of effectiveness with its optimized nanoviricide drug candidates against H1N1 influenza in a high infection, lethality mouse model study. The most effective FluCide candidate demonstrated a fifteen-fold (15X) greater lung viral load reduction as compared to Tamiflu, and a thirty-fold (30X) greater viral load reduction as compared to untreated animals. Tamiflu demonstrated a viral load reduction of only twofold (2X) compared to the untreated animals in this high infection, lethality study. This profound decrease in viral load was consistent with the observed substantial increase in length of survival upon nanoviricide treatment. Animals treated with this FluCide candidate survived for as long as 18.1 days on average, compared with only 7.8 days for Tamiflu treated animals. A survival length of 21 days would be considered indefinite survival in this animal model.



    The Company currently has five commercially important drug candidates in its pipeline. These include FluCide™, HIVCide™, HerpiCide™, DengiCide™, and a broad-spectrum nanoviricide eye drop formulation against viral infections of the eye. In addition, it continues to develop its novel ADIF™ (“Accurate Drug In Field”™) technologies which promise a way to attack novel viruses, whether man-made (bioterrorism) or natural (such as SARS), before they cause a pandemic. The Company is also developing broad-spectrum therapeutics against a number of different hemorrhagic viruses such as Ebola/Marburg, and viruses causing Neglected Tropical Diseases such as Rabies.



    “Now that we have a strong and wide pipeline, we plan to focus on taking our drug candidates further forward into the regulatory process,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “We have the necessary cash in hand for our immediate goals.”



    About NanoViricides:



    NanoViricides, Inc. (Welcome to NanoViricides, Inc.) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

  7. #7
    L'avatar di playars
    Data Registrazione
    Apr 2008
    Messaggi
    8,284
    Mentioned
    0 Post(s)
    Quoted
    1 Post(s)
    Potenza rep
    42949686

  8. #8
    L'avatar di playars
    Data Registrazione
    Apr 2008
    Messaggi
    8,284
    Mentioned
    0 Post(s)
    Quoted
    1 Post(s)
    Potenza rep
    42949686
    Citazione Originariamente Scritto da playars Visualizza Messaggio
    .....
    Immagini Allegate Immagini Allegate nnvc-nnvc.png 

  9. #9
    L'avatar di playars
    Data Registrazione
    Apr 2008
    Messaggi
    8,284
    Mentioned
    0 Post(s)
    Quoted
    1 Post(s)
    Potenza rep
    42949686
    O/S: 132,214,094
    Authorized: 300 million

  10. #10
    L'avatar di playars
    Data Registrazione
    Apr 2008
    Messaggi
    8,284
    Mentioned
    0 Post(s)
    Quoted
    1 Post(s)
    Potenza rep
    42949686
    Citazione Originariamente Scritto da playars Visualizza Messaggio
    Hey all my Ihub friends just sent Dr. Seymour a little Holiday note and this is his reply !!!!!!

    On Dec 23, 2010, at 11:21 AM
    Dear Dr. Seymour I just wanted to take a moment to wish you and your family a very Merry Christmas and to thank you for all the time and effort you put into NNVC each and every day of your life. NNVC is going to be a life changer for us all and it keeps me soooooooooooooo EXCITED !!!!!!!!!!! Something else that has me VERY excited is that NNVC has been invited to present at the Dengue Research meeting sponsored by the National Institutes Of Health. I would love to be there because I'm feeling something HUGE could be announced since Dr. Eva Harris of UC Berkeley and Dr. Harold Margolis Chief Of Dengue Branch Of CDC are attending !!!!!!!!! Well February is just around the corner and I CAN'T WAIT !!!!!!!
    Take care,
    Sincerely,
    Patricia

    Certainly OK to share
    All of this is public information

    Dear Patricia,
    Thanks for the kind wishes.
    I'm very excited about the prospects for the Company in 2011.
    We've gained a reputation in the scientific community for doing innovative work in viral therapeutics.
    Everything we're now doing is focused on document preparation for the FDA filings. That includes lots of laboratory and animal data on our various lead candidates.
    Some have complained that we're moving too slowly.

    I think that for a 5 year old company to have 9 drugs in the pipeline with 5 lead candidates for sequencing into the FDA and having done this for around $17M +/- is nothing short of amazing. And each of those candidates addresses a $1B+ market! We're actively seeking analytic and pharmaceutical chemists. I'm amazed that so many of those people feel more comfortable working for a large company where layoffs happen all the time rather than a rapid growth entrepreneurial company with some amazing technology. More people would enable us to move faster although we're still constrained by the available time in the University and government animal labs!

    That being said, 2011 should be a terrific year
    Sincerely,

    EUGENE SEYMOUR, MD, MPH
    Chief Executive Officer
    NANOVIRICIDES, INC
    Nanotechnology-based targeted anti-viral therapeutics

    Welcome to NanoViricides, Inc.
    [email protected]
    310-486-5677

Accedi